28 Jun 2021
Posted in Pharma
Diagnosed prevalent cases of uveitis to reach 1.9 million by 2029 in the 9MM, says GlobalData
The diagnosed prevalent cases of uveitis in the nine major markets (*9MM) are projected to increase from 1.7 million cases in 2019 to 1.9 million cases in 2029, equating to an annual growth rate (AGR) of 0.97%, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Uveitis – Epidemiology Forecast to 2029’, reveals that in 2029, the US will have the highest number of diagnosed prevalent cases of uveitis in the 9MM at 1.1 million, whereas Australia with nearly 9,800 cases will have the lowest number.
Adults ages 50 years and older accounted for more than 65% of the diagnosed prevalent cases of uveitis in the 9MM, while those ages 18–29 years accounted for less than 10%. This suggests that the risk of uveitis in individuals increases with age.
Uveitis has consistently been described in studies to be more common in women compared to men. These findings are in line with GlobalData’s estimates for sex-specific diagnosed prevalent cases. In the 9MM, the diagnosed prevalent cases of anterior uveitis were the predominant anatomical site of inflammation. In terms of etiology, non-infectious was the most common type for anterior uveitis, idiopathic uveitis was the most common among intermediate and panuveitis, and infectious causes were the most common etiology of posterior uveitis cases in the 9MM.
Bharti Prabhakar, MPH, Associate Project Manager at GlobalData, comments: “Uveitis is a serious sight-threatening disease that affects people of all ages and sexes. The studies used to build the forecast have found incidence rates and prevalence proportions that are significantly higher than previously believed, especially in the elderly population. Using these rates, GlobalData epidemiologists determined that the burden of uveitis is high in the elderly population. However, more population-based epidemiological studies are needed to elucidate the cause of the observed high incidence rates and prevalence proportions in the elderly population.”
*9MM: The US, 5EU (France, Germany, Italy, Spain, UK), Japan, Australia, and Canada